RECRUITING

The Role of Quantitative CT and Radiomic Biomarkers for Precision Medicine in Pulmonary Fibrosis

Talk to us

Conditions

Idiopathic Pulmonary FibrosisCTbiomarkersgene expressionradiomic markers

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This observational study involves obtaining 2 chest CT scans; a historical baseline CT within ±1 year of enrollment into PRECISIONS, and a follow-up CT (either historical or prospective) 12 months ± 180 days after the baseline CT. Many IPF patients will have a CT scan every 12 months for disease monitoring and cancer screening. Participants will have the option to share historical CTs only or they can choose to have a research CT done for the follow-up scan, if a scan for clinical purposes is not available.

Official Title

The Role of Quantitative CT and Radiomic Biomarkers for Precision Medicine in Pulmonary Fibrosis

Quick Facts

Study Start:2024-06-20
Study Completion:2029-05
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06323876

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:40 Years to 101 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. ≥ 40 years of age
  2. 2. Diagnosed with IPF according to 2018 ATS/ERS/JRS/ALAT confirmed by the enrolling investigator
  3. 3. Signed informed consent
  1. 1. Pregnancy or planning to become pregnant
  2. 2. Women of childbearing potential not willing to remain abstinent (refrain from heterosexual intercourse) or use two adequate methods of contraception, including at least one method with a failure rate of \<1% per year during study participation\*
  3. 3. Significant medical, surgical or psychiatric illness that in the opinion of the investigator would affect subject safety or potential to complete the research study
  4. * A woman is considered to be of childbearing potential if she is post-monarchical, has not reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus).

Contacts and Locations

Study Contact

Roselove Nunoo-Asare
CONTACT
4342436074
rnn3b@uvahealth.org
Diana Hsu, MA
CONTACT
NBR2DF@uvahealth.org

Principal Investigator

Noth Imre, MD
PRINCIPAL_INVESTIGATOR
Division of Pulmonary and Critical Care
John Kim
PRINCIPAL_INVESTIGATOR
Division of Pulmonary and Critical Care

Study Locations (Sites)

University of Virginia
Charlottesville, Virginia, 22908
United States

Collaborators and Investigators

Sponsor: University of Virginia

  • Noth Imre, MD, PRINCIPAL_INVESTIGATOR, Division of Pulmonary and Critical Care
  • John Kim, PRINCIPAL_INVESTIGATOR, Division of Pulmonary and Critical Care

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-06-20
Study Completion Date2029-05

Study Record Updates

Study Start Date2024-06-20
Study Completion Date2029-05

Terms related to this study

Keywords Provided by Researchers

  • CT
  • biomarkers
  • gene expression
  • radiomic markers

Additional Relevant MeSH Terms

  • Idiopathic Pulmonary Fibrosis